The US Department of Justice (DOJ) has filed an antitrust lawsuit to prevent planned megamergers in the health insurance industry.
The US Department of Justice (DOJ) filed an antitrust lawsuit earlier today to prevent planned megamergers in the health insurance industry. Citing the mergers as a potential barrier to innovation in the sector, the DOJ said it could also raise healthcare costs.
The lawsuit says, “Today, the industry is dominated by five large insurers commonly referred to as 'the big five. In a scramble to become even bigger, four of the big five now propose to merge: Anthem seeks to buy Cigna for $54 billion, and Aetna seeks to acquire Humana for $37 billion. These mergers would reshape the industry, eliminating two innovative competitors — Cigna and Humana — at a time when the industry is experimenting with new ways to lower healthcare costs.”
The lawsuit to block the merger between Anthem-Cigna and Aetna-Humana has support from 9 states and the District of Columbia. The insurance commissioner of California, which is 1 of the 9 on the lawsuit, had declared the Anthem-Cigna deal would be anti-competitive and could lower the quality of patient care. Aetna, meanwhile, had been taking steps to prevent the development of antitrust concerns, such as plans to sell Medicare Advantage assets.
Anthem released a statement in response to today’s lawsuit, which states: “Today’s action by the Department of Justice is an unfortunate and misguided step backwards for access to affordable healthcare for America. The DOJ’s action is based on a flawed analysis and misunderstanding of the dynamic, competitive and highly regulated healthcare landscape and is inconsistent with the way that the DOJ has reviewed past healthcare transactions,” adding, “Anthem is fully committed to challenging the DOJ’s decision in court but will remain receptive to any efforts to reach a settlement with the DOJ that will allow us to complete the transaction and deliver its benefits at a critical time when American consumers are seeking high quality healthcare services with greater value at less cost.”
Cigna released a statement that predicted the planned merger could be pushed to 2017 “if at all.”
The statement from Aetna and Humana read, “Aetna and Humana Inc. today announced plans to vigorously defend the companies’ pending merger in response to a U.S. Department of Justice (DOJ) lawsuit seeking to block the transaction. A combined company is in the best interest of consumers, particularly seniors seeking affordable, high-quality Medicare Advantage (MA) plans.”
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Collecting SDOH Data Can Assess Risk of Medical Nonadherence, Improve HEI and Star Ratings
April 18th 2024At the Academy of Managed Care Pharmacy (AMCP) 2024 annual meeting, a panel of presenters explored changes coming to Medicare that incorporate social determinants of health (SDOH) data to improve patient and health system outcomes.
Read More
Many Patients With Psoriasis in Clinical Trials Experience Nocebo Effects, Study Finds
April 18th 2024Half of patients exposed to placebo in clinical trials experienced adverse events (AEs), which may be partially explainable by nocebo effects, according to a recent review and meta-analysis.
Read More